Unknown

Dataset Information

0

Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway.


ABSTRACT: Various clinical studies have determined that aspirin shows anticancer effects in many human malignant cancers, including human epidermal growth factor receptor-2 (HER-2)-positive breast cancer. However, the anti-tumor mechanism of aspirin has not been fully defined. The aim of this study was to determine the role of Compound C in enhancing the anticancer effect of aspirin. HER-2-positive breast cancer cell lines were treated with aspirin with or without Compound C pre-treatment; their phenotypes and mechanisms were then analyzed in vitro and in vivo. Aspirin exhibited anticancer effects in HER-2-positive breast cancer by inhibiting cell growth and inducing apoptosis through the activation of AMP-activated protein kinase (AMPK). Unexpectedly, pre-treatment with Compound C, a widely used AMPK inhibitor, induced robust anticancer effects in cells compared to aspirin monotherapy. This anticancer effect was not distinct in HER-2 negative breast cancer MDA-MB-231 cells and may be due to the inhibition of lipid metabolism mediated by c-myc. Besides, c-myc re-expression or palmitic acid supply could partially restored cell proliferation. Aspirin exhibits anticancer effects in HER-2-positive breast cancer by regulating lipid metabolism mediated by c-myc, and Compound C strengthens these effects in an AMPK-independent manner. Our results potentially provide a novel therapeutic strategy exploiting combined aspirin and Compound C therapy for HER-2-positive breast cancer, which acts by reducing de novo lipid synthesis.

SUBMITTER: Wu Y 

PROVIDER: S-EPMC6990926 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway.

Wu Ying Y   Yan Bohua B   Xu Wenqin W   Guo Lili L   Wang Zhe Z   Li Guoyin G   Hou Niuniu N   Zhang Jian J   Ling Rui R  

International journal of biological sciences 20200101 4


Various clinical studies have determined that aspirin shows anticancer effects in many human malignant cancers, including human epidermal growth factor receptor-2 (HER-2)-positive breast cancer. However, the anti-tumor mechanism of aspirin has not been fully defined. The aim of this study was to determine the role of Compound C in enhancing the anticancer effect of aspirin. HER-2-positive breast cancer cell lines were treated with aspirin with or without Compound C pre-treatment; their phenotype  ...[more]

Similar Datasets

| S-EPMC7224363 | biostudies-literature
| S-EPMC9087915 | biostudies-literature
| S-EPMC11841222 | biostudies-literature
| S-EPMC3954437 | biostudies-literature
| S-EPMC9361555 | biostudies-literature
| S-EPMC11302888 | biostudies-literature
| S-EPMC8640802 | biostudies-literature
| S-EPMC11606862 | biostudies-literature
| S-EPMC5850832 | biostudies-literature
| S-EPMC9558994 | biostudies-literature